University of Colorado Anschutz

What University of Colorado Anschutz does

University of Colorado Anschutz is a public academic medical campus located on the former Fitzsimons Army Medical Center site in Aurora, Colorado, formed through the 2004 consolidation of the University of Colorado Health Sciences Center and the University of Colorado at Denver. The institution operates three integrated mission areas — education, research, and patient care — across six professional schools (Medicine, Nursing, Pharmacy, Dental Medicine, Public Health, and Graduate School), enrolling approximately 4,500 degree-seeking students in over 40 degree programs and serving more than 3 million patient visits annually through its primary clinical partners, UCHealth University of Colorado Hospital and Children's Hospital Colorado. Research output is anchored by $890 million in annual funding ($762M sponsored awards plus $128M philanthropic) and includes flagship capabilities such as the Gates Institute's CD64-directed CAR T-cell therapy (the first FDA-cleared therapy developed entirely on a university campus), the world's first higher-cortex brain-computer interface surgery, and AI-driven diagnostics (e.g., 82–91% accuracy retinal image models for neonatal pulmonary conditions, 87% accuracy Barrett's esophagus recurrence prediction, and Verily Refinery achieving >95% accuracy on complex clinical variables).

The business model combines four revenue streams: tuition and educational program fees across the six schools; sponsored research awards from federal (NIH, NSF, ARPA-H, NIDDK), state, and private funders; clinical care revenue routed through UCHealth; and philanthropic gifts supporting research and capital projects. Strategic capital deployment is active, including a $22.5M acquisition of the Benson Hotel & Faculty Club for patient/family accommodations (March 2026) and participation in Verily Health Inc.'s $300M funding round alongside UCHealth, Alphabet, and Series X Capital. Distribution spans on-campus and NC-SARA-authorized distance education, an embedded partnership ecosystem (ConcertAI CancerLinQ, RefinedScience JV, Mission Bio, City of Hope, Colorado State University, SOL Mental Health), and 57 NCCN cancer guideline adaptations covering over 85% of Sub-Saharan Africa's cancer burden. The institution is led by Chancellor Donald M. Elliman Jr. and CFO Terri Carrothers, operates under The Regents of the University of Colorado, and holds accreditations from HLC, LCME, ACGC, and NC-SARA.

Name

University of Colorado Anschutz

Legal name

The Regents of the University of Colorado

Website

https://cuanschutz.edu

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

University of Colorado Anschutz is a public academic medical campus in Aurora, Colorado, operating six professional schools, 40+ degree programs for 4,500 students, and $890M in annual research funding across oncology, neuroscience, and population health, serving over 3 million patient visits annually through UCHealth and Children's Hospital Colorado partnerships.

Ownership category

akta.pro rank

Product category

Academic Medical Center

NAICS

Colleges, Universities, and Professional Schools (6113), General Medical and Surgical Hospitals (6221)

SIC

Services-Hospitals (8060), Services-Health Services (8000), Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC)

akta.pro secondary industries

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Medical Schools (MD/DO Granting) (EDAHAGAB), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

Keywords

• Academic medical center
• Health sciences education
• Biomedical research
• Clinical care services
• Medical degree programs

Headquarters

HQ city

Aurora

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Tuition and Educational Programs: Revenue from degree programs across six schools including Medicine, Nursing, Pharmacy, Dental Medicine, Public Health, and Graduate School
2. Research Grants and Sponsored Awards: $762M in sponsored awards annually from federal, state, and private research funding
3. Clinical Care Revenue: Patient care services through UCHealth University of Colorado Hospital serving over 3 million patient visits annually
4. Philanthropic Gifts: $128M in annual philanthropic gifts supporting research initiatives

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

University of Colorado Anschutz is an academic medical campus offering over 40 degree programs across six schools (Medicine, Nursing, Pharmacy, Dental Medicine, Public Health, and Graduate School). The institution delivers advanced biomedical research and clinical care through partnerships with UCHealth University of Colorado Hospital and Children's Hospital Colorado, serving more than 3 million patient visits annually with $890 million in annual research funding.

Product overview

University of Colorado Anschutz is an academic medical campus combining education, research, and patient care across six professional schools (Medicine, Nursing, Pharmacy, Dental Medicine, Public Health, and Graduate School). The institution offers over 40 degree programs and handles over 3 million patient visits annually with approximately $890M in annual research funding. CU Anschutz's technology portfolio includes AI-enabled clinical platforms (Verily Refinery for data transformation, CancerLinQ for oncology insights), novel therapeutics (CD64-directed CAR T-cell therapy, the first FDA-cleared therapy developed entirely on a university campus), medical devices (higher-cortex BCI for paralysis restoration), and decision support tools (Parkinson's DBS decision tool). The institution also leverages single-cell multiomics analysis via the Mission Bio Tapestri platform for CAR-T therapy research.

Differentiator

Problem solved

Functional benefit

Brands

• School of Medicine: Medical education and research school at CU Anschutz
• College of Nursing
• Skaggs School of Pharmacy and Pharmaceutical Sciences
• School of Dental Medicine
• Colorado School of Public Health
• Graduate School

Products and services

• School of Medicine (MD Program)
• College of Nursing Programs
• Skaggs School of Pharmacy and Pharmaceutical Sciences
• School of Dental Medicine
• Colorado School of Public Health
• Graduate School Programs
• CD64-Directed CAR T-Cell Therapy
• Higher-Cortex Brain Computer Interface (BCI)
• Verily Refinery Data Platform
• CancerLinQ Platform Participation
• Parkinson's DBS Decision-Making Tool
• Quality Assurance and Regulatory Affairs Certificate Program

Quantifiable outcome

• First-in-U.S. FDA clearance for campus-developed CAR T-cell therapy for acute myeloid leukemia
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability14 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core.

• ConcertAIcoreTechnology or Integration · 1 May 2026University of Colorado Anschutz Cancer Center joined ConcertAI's CancerLinQ network, expanding the platform's real-world oncology data coverage. CancerLinQ leverages AI to aggregate and analyze data from over 900 care sites across all 50 states.
• SOL Mental HealthcoreStrategic or Co-development Partner · 1 April 2026Partnership with CU Anschutz Internal Medicine Residency program to provide therapy and psychiatry services to residents, featuring opt-out appointments with confidential provider matching.
• Mission BiocoreStrategic or Co-development Partner · 1 April 2026Research collaboration using Mission Bio's Tapestri single-cell multiomics platform to profile vector copy number in CAR-T therapies, achieving 99.2-99.9% sensitivity and 98.8-99.6% specificity.
• City of HopecoreStrategic or Co-development Partner · 1 April 2026Research partner with Children's Hospital Colorado and University of Colorado Anschutz on Mission Bio Tapestri platform study for CAR-T therapy vector copy number profiling.
• Children's Hospital ColoradocoreStrategic or Co-development Partner · 1 April 2026Research partner on CAR-T therapy studies and pediatric clinical trial following CAR T-cell therapy FDA clearance.
• Verily Health Inc.coreStrategic or Co-development Partner · 1 March 2026Multi-year strategic collaboration to transform healthcare data usage and patient care delivery using AI and digital technology. Verily's platform aggregates biomedical data to develop AI/ML models across oncology, cardiovascular, neuroscience, and other therapeutic areas. Initial results show over 95% accuracy in Acute Myeloid Leukemia analysis.
• Colorado State UniversitycoreStrategic or Co-development Partner · 1 February 2026'Lab to Labrador' collaboration on trauma research focusing on tranexamic acid for severe bleeding, aiming to accelerate approval processes through comparative studies of injury responses in humans and dogs.
• RefinedSciencecoreStrategic or Co-development Partner · 1 October 2025Joint venture between CU Anschutz and UCHealth focused on drug discovery, working with Verily to develop advanced analytical tools for complex biological data.
• UCHealth University of Colorado HospitalcoreStrategic or Co-development PartnerPrimary academic medical center partner providing clinical care and hosting clinical trials. Over 3 million patient visits annually.
• Children's Hospital ColoradocoreStrategic or Co-development PartnerNationally recognized pediatric academic medical center partnership for children's healthcare and research collaborations.
• University of Colorado MedicinecoreStrategic or Co-development PartnerFaculty practice plan providing clinical care through CU Anschutz physicians.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Vanderbilt University Medical Center: Vanderbilt is a peer academic medical center with comparable biomedical informatics capabilities, large-scale biobanking (BioVU), and NIDDK-funded diabetes research consortium participation. Both compete for federal informatics and precision medicine grants.
• University of California, San Francisco (UCSF): UCSF is a leading public academic medical center with similar tripartite mission of research, education, and patient care. It competes with CU Anschutz for NIH funding, top faculty, and clinical trial leadership in oncology and translational medicine.
• NYU Langone Health: NYU Langone is a peer academic medical center with strong translational research, multiple health science schools, and similar scale of sponsored research funding. Both compete for top U.S. News rankings and clinical trial leadership.
• Johns Hopkins Medicine: Johns Hopkins is a peer top-5 research institution combining medical education, biomedical research, and patient care. It competes directly for federal research funding, faculty recruitment, and specialized clinical referrals in oncology and neuroscience.
• University of Pennsylvania Health System: Penn Medicine is a top-tier academic medical center with comparable scope across six health science schools, robust CAR T-cell therapy research (pioneered the field), and similar NIH funding scale. Both institutions are leaders in translational gene and cellular therapy research.
• Washington University in St. Louis (BJC HealthCare): Washington University School of Medicine is a comparable top-tier research institution with strong NIH funding, BJC hospital partnership structure, and leading genomics research. Both compete for precision medicine and clinical research leadership.
• Duke University Health System: Duke is a comparable academic medical center with strong translational research programs, NCI-designated cancer center, and clinical partnerships. Both institutions compete for clinical trial enrollment and biotech industry collaboration.
• Stanford Medicine: Stanford Medicine operates as a comparable academic medical center with BCI research leadership (BrainGate program), strong AI/healthcare integration, and substantial NIH funding. It competes for translational research talent and clinical trial sponsorship.

Others

• ConcertAI: ConcertAI is an oncology data platform partner whose CancerLinQ network CU Anschutz joined. Comparable as a healthcare AI ecosystem participant rather than a direct competitor, representing the broader landscape of clinical research data infrastructure providers.
• Verily Health Inc. Verily is a strategic AI/data platform partner (and recent CU Anschutz investor) working with the institution to develop AI-native precision health tools. They are comparable as collaborators in translational data infrastructure rather than direct competitors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/cuanschutz
• Facebookfacebook.com/CUAnschutzMed
• LinkedInlinkedin.com/school/university-of-colorado-anschutz-medical-campus
• Instagraminstagram.com/CUAnschutz

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries4 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about University of Colorado Anschutz